News
-
-
News
Press Release
Ingenia Announces First-in-Human Dosing of IGT-303 for CKD/DKD
- Nov 21,2025
- INGENIA
INGENIA is pleased to announce another significant clinical milestone: IGT-303, the company’s lead clinical asset, has been successfully administered in humans for the first time (FIH) on November 19, 2025. IGT-303 is being developed for the treatment of Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD), representing a major advancement in expanding Ingenia’s TIE2-targeted therapeutic platform beyond ophthalmology and into the nephrology field.
This subsequent clinical milestone underscores Ingenia’s continued progress in building a robust pipeline and delivering innovative, first-in-class therapies by directly activating the TIE2 pathway. The initiation of human dosing for IGT-303 marks an important step forward as Ingenia advances its mission to transform patient care across multiple vascular-related diseases.